Thank you, drbio, for the posts about the PPL drug candidate in emphysema and CF. I have extracted the tabular data from PPL’s phase-2 study and presented it below to illustrate just how bad this data was.
At all but the highest dose of 250mg/day, efficacy was essentially no better than placebo:
TABLE 1: NUMBER OF EXACERBATIONS AS A PERCENTAGE OF THE PLACEBO RATE
All Exacerbations Severe Exacerbations Dose Group % of placebo p-value % of placebo p-value 250 mg/day 75% 0.21 48% 0.08 125 mg/day 81% 0.35 94% 0.85 62.5 mg/day 106% 0.88 104% 0.91
TABLE 2: LUNG FUNCTION: PERCENTAGE DIFFERENCE FROM PLACEBO AT SIX MONTHS
Definitions: VC is vital capacity, i.e. lung volume normal breathing. FVC is forced vital capacity, i.e. lung capacity breathing out hard. FEV-1 is forced expiry volume in one second, i.e. the maximum amount breathed out in one second.
-- To show data in tabular form on iHub, use the following formatting commands:
“pre” enclosed in square brackets at the beginning of tabular data, including any headers.
“/pre” enclosed in square brackets at the end of the last row of tabular data.
All text between the above delimiters will be displayed in a fixed-width font for proper alignment.
>> I think I may know who RIDGERUNNER is. I will ask him to post on this site. <<
If ridge_runner is who I suspect he is, I would not expect him to be posting about GENR very often. For certain individuals, touting a company on public message boards could be construed as a conflict of interest. FWIW